Algorithms based on prostate-specific antigen (PSA), free psa, digital rectal examination and prostate volume reduce false-postitive psa results in prostate cancer screening

被引:56
|
作者
Finne, P
Finne, R
Bangma, C
Hugosson, J
Hakama, M
Auvinen, A
Stenman, UH
机构
[1] Univ Helsinki, Dept Clin Chem, Biomedicum Helsinki A424, FIN-00029 Helsinki, Finland
[2] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland
[3] Swedsih Polytech, Vaasa, Finland
[4] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[5] Univ Gothenburg, Dept Urol, Gothenburg, Sweden
[6] Finnish Canc Registry, FIN-00170 Helsinki, Finland
关键词
prostate cancer; screening; logistic regression; neural network; prostate-specific antigen;
D O I
10.1002/ijc.20250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our objective was to determine whether multivariate algorithms based on serum total PSA, the free proportion of PSA, age, digital rectal examination and prostate volume can reduce the rate of false-positive PSA results in prostate cancer screening more effectively than the proportion of free PSA alone at 95% sensitivity. A total of 1,775 consecutive 55- to 67-year-old men with a serum PSA of 4-10 mug/l in the European Randomized Study of Screening for Prostate Cancer were included. To predict the presence of cancer, multivariate algorithms were constructed using logistic regression (LR) and a multilayer perceptron neural network with Bayesian regularization (BR-MLP). A prospective setting was Simulated by dividing the data set chronologically into one set for training and validation (67%, n = 1,183) and one test set (33%, n = 592). The diagnostic models were calibrated using the training set to obtain 95% sensitivity. When applied to the test set, the LR model, the BR-MLP model and the proportion of free PSA reached 92%, 87% and 94% sensitivity and reduced 29%, 36% and 22% of the false-positive PSA results, respectively. At a fixed sensitivity of 95% in the test set, the LR model eliminated more false-positive PSA results (22%) than the proportion of free PSA alone (17%) (p < 0.001), whereas the BR-MLP model did not (19%) (p = 0.178). The area under the ROC curve was larger for the LR model (0.764, p = 0.030) and the BR-MLP model (0.760, p = 0.049) than for the proportion of free PSA (0.718). A multivariate algorithm can be used to reduce unnecessary prostate biopsies in screening more effectively than the proportion of free PSA alone, but the algorithms will require updating when clinical practice develops with time. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [1] Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age
    Partin, AW
    Catalona, WJ
    Southwick, PC
    Subong, ENP
    Gasior, GH
    Chan, DW
    [J]. UROLOGY, 1996, 48 (6A) : 55 - 61
  • [2] Prostate cancer and prostate-specific antigen (PSA) screening in AustriaProstatakarzinom und PSA-Screening in Österreich
    Christian Vutuc
    Eva S. Schernhammer
    Gerald Haidinger
    Thomas Waldhör
    [J]. Wiener klinische Wochenschrift, 2005, 117 : 457 - 461
  • [3] THE DIAGNOSTIC-ACCURACY OF DIGITAL RECTAL EXAMINATION, TRANSRECTAL ULTRASONOGRAPHY, PROSTATE-SPECIFIC ANTIGEN (PSA) AND PSA DENSITY IN PROSTATE CARCINOMA
    AKDAS, A
    TARCAN, T
    TURKERI, L
    CEVIK, I
    BIREN, T
    GURMEN, N
    [J]. BRITISH JOURNAL OF UROLOGY, 1995, 76 (01): : 54 - 56
  • [4] Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Revisiting the Evidence
    Carter, H. Ballentine
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1866 - 1868
  • [5] PROSTATE-SPECIFIC ANTIGEN (PSA)
    HOWANITZ, JH
    [J]. DISEASE MARKERS, 1993, 11 (01) : 3 - 10
  • [6] Update on prostate-specific antigen (PSA)-based screening
    Suzuki, Hiroyoshi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (09) : 711 - 711
  • [7] Clinical evaluation of free PSA total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer
    Filella, X
    Alcover, J
    Molina, R
    Rodriguez, A
    Carretero, P
    Ballesta, AM
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) : 1226 - 1229
  • [8] Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level
    Törnblom, M
    Norming, U
    Becker, C
    Lilja, H
    Gustafsson, O
    [J]. BJU INTERNATIONAL, 2001, 87 (07) : 638 - 642
  • [9] Inappropriate prostate-specific antigen (PSA) screening
    不详
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2007, 120 (1266) : 133 - 134
  • [10] PROSTATE-SPECIFIC ANTIGEN (PSA) IN PROSTATE DISEASE
    PEYRET, C
    LEROY, M
    TEILLAC, P
    RABAUD, B
    NAJEAN, Y
    LEDUC, A
    [J]. JOURNAL DE BIOPHYSIQUE ET DE BIOMECANIQUE, 1987, 11 (03): : 125 - 125